Sonoma Pharma

Q1 FY2027 EarningsQ1 FY27 beat consensus across all key financial metrics, driven by a 141% surge in U.S. revenue and improved manufacturing efficiencies. Revenue of $6.4M significantly exceeded the $5.0M estimate, while gross margin reached 40.2% (vs. 39.4% expected). Operating loss of $40K and net loss of $330K were both substantially narrower than anticipated, benefiting from scaled operations and strict cost controls. Operating cash flow missed the modest positive mean estimate due to working capital builds, but improved significantly YoY.